Wisconsin Scientists Crack Cancer Treatment Manufacturing

Scientists at the University of Wisconsin have found a way to make cutting-edge cancer treatments far simpler to manufacture, a discovery that could help more patients access these life-saving medicines.

The team cracked a stubborn problem with antibody-drug conjugates, or ADCs. These smart therapies work like guided missiles, using antibodies to find cancer cells and deliver powerful drugs directly to them while leaving healthy cells alone.

ADCs are already helping cancer patients, but drug companies struggle to make them consistently. Current methods produce batches where each molecule looks slightly different, making quality control a nightmare and slowing down production.

Professor Weiping Tang and his team at the UW School of Pharmacy kept running into this same frustration. "We tried a number of different strategies, and they all worked at creating ADCs, but we weren't happy with any of them," Tang says.

After months of trial and error, they developed a completely new approach. The technique removes the natural variation in antibodies before attaching the cancer-fighting drug, creating identical molecules every single time.

The real game-changer? They simplified one crucial step from more than a dozen separate procedures down to just two. That means faster production, lower costs, and treatments that work exactly the same way in every batch.

"You can precisely measure each batch, know exactly how many drug molecules are attached and improve batch-to-batch consistency," Tang explains.

The discovery came from an unexpected place. Tang's lab was working on an entirely different approach to fighting disease when they realized their new method could solve the ADC manufacturing problem too.

In laboratory tests, the new ADCs killed specific cancer cells while leaving other cells unharmed. The platform is flexible enough to create multiple types of targeted medicines, potentially treating diseases far beyond cancer.

The Ripple Effect

The impact is already spreading beyond the lab. GlycoBridge Biosciences, a startup born from this research, has licensed the technology and is preparing it for commercial use.

The company recently won funding from the Wisconsin Entrepreneurship Hub and is already in talks with biotech companies, manufacturers, and investors. Tang says interest in the platform has been strong because it solves real problems the industry faces every day.

"We started this work because we needed a better way to make our own molecules," Tang says. "Then we realized it could be broadly useful."

The findings appeared in the journal Angewandte Chemie in August 2026, backed by support from the National Institutes of Health.

For Tang and his team, this is just the beginning of what their discovery can do.